p53-based anti-cancer therapies: An empty promise?

  title={p53-based anti-cancer therapies: An empty promise?},
  author={Nikolas Desilet and Tessa N. Campbell and Francis Y. M. Choy},
  journal={Current issues in molecular biology},
  volume={12 3},
Since its discovery in 1979, p53 has become the focus of intensive cancer-based research in laboratories around the world. The p53 protein mediates critical cellular functions including the response to genotoxic stress, differentiation, senescence, and apoptosis, and has been shown to be mutated in a large proportion of human cancers. These observations led many to speculate that targeting the p53 pathway would result in the development of successful anti-cancer treatments. In spite of this, 30… CONTINUE READING

From This Paper

Figures, tables, and topics from this paper.

Explore Further: Topics Discussed in This Paper


Publications citing this paper.
Showing 1-8 of 8 extracted citations


Publications referenced by this paper.
Showing 1-10 of 46 references

30 years and a long way into p53 research.

The Lancet. Oncology • 2009
View 8 Excerpts
Highly Influenced

p53 as a target for anti-cancer drug development.

Critical reviews in oncology/hematology • 2006
View 4 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…